| Document |
Document Title |
|
WO/2011/141703A1 |
The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient enca...
|
|
WO/2011/141704A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid- lipid particles that provide efficient encapsulation of nucleic...
|
|
WO/2011/138665A1 |
The present invention provides dihydroorotate dehydrogenase inhibitors of formula (I), methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorde...
|
|
WO/2011/138655A1 |
Monomers having formula (I) and process for their synthesis which comprises the etherification reaction of a halogen-derivative (Z = C1, Br, I) having formula (III) with the hydroxyl group of the glycerol derivative (IV), according to th...
|
|
WO/2011/135046A1 |
A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising...
|
|
WO/2011/133729A2 |
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the...
|
|
WO/2011/132712A1 |
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...
|
|
WO/2011/122449A1 |
Disclosed are: a nonaqueous electrolyte solution that is capable of improving the low temperature load characteristics after charging and storage at high temperatures; an electrochemical element which uses the nonaqueous electrolyte solu...
|
|
WO/2011/118812A1 |
Provided is an unprecedented composition that is not a conventional symptomatic treatment, but makes possible the fundamental treatment of current neurodegenerative diseases by inhibiting oxidative-stress induced nerve-cell death. The di...
|
|
WO/2011/109276A1 |
The present invention generally relates to methods for the synthesis of catalysts, including epoxidation catalysts, and related compounds and catalyst compositions. Embodiments described herein may provide efficient processes for providi...
|
|
WO/2011/104719A1 |
The present invention generally relates to a process for making polyol ethers by reacting a polyol and a carbonyl compound together in the presence of hydrogen gas and a bimetal palladium hydrogenation catalyst on a carbon support.
|
|
WO/2011/105565A1 |
Disclosed are: a high purity aromatic methyl alcohol compound which is suppressed in the inclusion of a by-product, namely the inclusion of a bis(arylmethyl) ether compound; a high purity aromatic methyl alcohol composition which has exc...
|
|
WO/2011/101245A1 |
The invention relates to nitrooxyderivatives of Gamma- aminobutyric acid analogs (GABA analogs) for treating neuropathic pain and in particular diabetic neuropathy. The invention also relates to pharmaceutical formulation comprising such...
|
|
WO/2011/101180A1 |
Fragrances having a fresh odor are usually very volatile and are therefore not very economical when used in typical applications such as e.g. washing or cleaning processes. They therefore have to be used in relatively large quantities to...
|
|
WO/2011/092284A1 |
The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.
|
|
WO/2011/088561A1 |
The present disclosure provides novel compounds as well as uses, methods, and compositions of treating, or reducing the risk of, HIV-infection.
|
|
WO/2011/084649A2 |
Redox flow devices are described in which at least one of the positive electrode or negative electrode-active materials is a semi-solid or is a condensed ion-storing electroactive material, and in which at least one of the electrode-acti...
|
|
WO/2011/080313A1 |
The present invention encompasses novel piperin compounds of general formula (I) wherein R1, R2, R3, m and n are defined as in claim 1, which are suitable for the prevention and/or treatment of diseases mediated by modulation of GABAA re...
|
|
WO/2011/073100A1 |
The invention relates to novel acylmethylene-1,3-dioxolanes and acylmethylene-1,4-dioxanes of the general formula (I), in which R1, R2, R3 and n are defined as in the description, and to a novel method for the production thereof. Acylmet...
|
|
WO/2011/073950A1 |
The present invention relates to the preparation of a class of novel, optically active compounds derived from oligomeric proanthocyanidins (OPCs), more particularly to oligomers of epicatechin. These compounds include multidentate ligand...
|
|
WO/2011/073101A1 |
The invention relates to a method for producing 1-alkyl- or 1-aryl-substituted 5-pyrazole-carboxylic acid derivatives, having the steps of converting substituted 1,3-dioxolanes and 1,4-dioxanes into 1-alkyl- or 1-aryl-substituted dihydro...
|
|
WO/2011/074484A1 |
The present invention relates to a process for preparing 1-O-acyl-2-deoxy-2-fluoro-4-thio-ƒﾀ-D-arabinofuranoses having formula I and intermediates thereof: wherein R1 represents -C(O)-C1-C6-alkyl or -C(O)-aryl; and R2 represents C1-C6...
|
|
WO/2011/073479A1 |
Use of the phenantrenic alkaloids seconeolitsine and N-methyl-seconeolitsine for the manufacture of medicaments. More particularly the use is described of the said compounds for the manufacture of antibiotics, especially for the treatmen...
|
|
WO/2011/064790A1 |
A novel process for making Renin inhibitors like Aliskiren is disclosed. Its novel intermediate compounds and method of making them are also disclosed.
|
|
WO/2011/065528A1 |
Disclosed is a process for ethylene carbonate production which comprises steps of reacting carbon dioxide with ethylene oxide in the presence of a catalyst to obtain a liquid reaction mixture that contains ethylene carbonate and purifyin...
|
|
WO/2011/061452A2 |
The present invention relates to a compound having the following formula (I): where R1 is H or an alkyl group; A1 is a straight or branched divalent alkylene radical, A2 is a -O- A4-O- radical, and A4 is a straight or branched divalent a...
|
|
WO/2011/059042A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/059731A1 |
The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
|
|
WO/2010/131054A9 |
The present invention provides redox drug derivatives. In particular, 9-fluoro-2,3- dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido
[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-pip...
|
|
WO/2011/053948A1 |
The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the end...
|
|
WO/2011/047432A1 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
WO/2011/047466A1 |
The present application relates to processes for the preparation of intermediates useful in the manufacture of oseltamivir and the H3PO4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate and compounds ...
|
|
WO/2011/048053A1 |
Difluoroethylene carbonate, trifluoroethylene carbonate and tetrafluoroethylene carbonate are synthesized from dichloroethylene carbonate, trichloroethylene carbonate and tetrachloroethylene carbonate with fluorinating agents, e.g. alkal...
|
|
WO/2011/046954A1 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/043480A1 |
Disclosed is a homocysteine synthase inhibitor which is useful for the prevention or treatment of diseases associated with a homocysteine synthase. Specifically disclosed is a compound represented by general formula (I) [wherein each sym...
|
|
WO/2011/042288A1 |
The present invention relates to a material including a (poly)glycerol group and a hydrophobic group connected together by a heteroatom, to a method for synthesizing same, and to the use thereof as a surfactant. The present invention als...
|
|
WO/2011/038857A2 |
Suggested are alkoxylated glycerol acetals according to formulae (Ia) and (Ib) in which R1 stands for a linear or branched, saturated or unsaturated and optionally substituted hydrocarbyl residue comprising 6 to 22 carbon atoms and O or ...
|
|
WO/2011/036283A2 |
Difluoroethylene carbonate, trifluoroethylene and tetrafluoroethylene carbonate are produced by the reaction between elemental fluorine and ethylene carbonate or fluorinated ethylene carbonates with a lower degree of fluorination.
|
|
WO/2011/036281A1 |
A process for the manufacture of fluoroethylene carbonate, difluoroethylene carbonate, fluoromethyl methyl carbonate and difluorinated dimethyl carbonate from ethylene carbonate and dimethyl carbonate and F2 is described wherein the fluo...
|
|
WO/2011/036293A2 |
The present invention provides inter alia a method for handling fluorinated organic carbonates such that degradation reactions are minimized or even completely suppressed and hence initial purity of fluorinated organic carbonatesis essen...
|
|
WO/2011/032095A1 |
A ketal ester of an oxocarboxylic acid and a process to make the same, where the ketal ester is of Structure (I): wherein a is 0 or an integer from 1 to 12; n is 0 or 1; R1 is a linear alkyl, aryl, arylalkylene, or branched alkyl group w...
|
|
WO/2011/025056A1 |
Disclosed is a chromene compound which has a skeleton represented by formula (1) and shows a double peak profile. In formula (1), Z represents a group represented by any of formulae (2) [wherein R1 represents an electron-donating group h...
|
|
WO/2011/020830A1 |
Process for the destillative purification of fluoroethylene carbonate Crude fluoroethylene carbonate obtained by the fluorination of ethylene carbonate and elemental fluorine containing not more than 5 % by weight of HF is purified by at...
|
|
WO/2011/009826A2 |
Chalcone derivatives of the general formula (I), wherein two from among A, B and Z which are adjacent to each other are linked and form a moiety selected from -O-(CH2)n-S(O)m-, -S(O)m-(CH2)n-O- and -O-(CH2)n-O-, and the remaining one fro...
|
|
WO/2011/011420A2 |
The present invention relates to new 3,4-methylenedioxyphenyl inhibitors of GABA aminotransferase activity and/or GABA reuptake transporter activity, pharmaceutical compositions thereof, and methods of use thereof. Formula (I)
|
|
WO/2011/003575A1 |
A process for producing a perfluorinated functional compound is disclosed, which comprises: A. converting an at least partially hydrogenated alcohol into an at least partially hydrogenated fluoroformate compound; B. reacting said at leas...
|
|
WO/2011/000830A1 |
The present invention provides a process for the production of monoethylene glycol, said process comprising the steps of: (a) reacting ethylene oxide with a ketone in the presence of a solid acidic catalyst to form a ketal; and (b) hydro...
|
|
WO/2011/000106A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic ...
|
|
WO/2010/151558A1 |
Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyal...
|
|
WO/2010/144959A1 |
The present invention relates to analogues of anti-fibrotic agents having the formula (I) with the substituents as described within the specification. The present invention also relates to methods for their preparation.
|
